[1] Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35(6):1232-8. Epub 2012/04/12. doi: 10.2337/dc11-1926.
PubMed PMID: 22492586; PubMed Central PMCID: PMCPMC3357223.
[2] Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582-92. Epub 2013/09/13. doi: 10.1007/s00125-013-3039-1. PubMed PMID: 24026211; PubMed Central PMCID:
PMCPMC3825495.
[3] Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Diabetes Obes Metab. 2013;15(4):372-82. Epub 2013/01/03. doi: 10.1111/dom.12054. PubMed PMID: 23279307; PubMed Central PMCID: PMCPMC3593184.
[4] Stenlof K, Cefalu WT, Kim KA, Jodar E, Alba M, Edwards R, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014;30(2):163-75.
Epub 2013/10/01. doi: 10.1185/03007995.2013.850066. PubMed PMID: 24073995.
[5] Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
Lancet. 2013;382(9896):941-50. Epub 2013/07/16. doi: 10.1016/S0140-6736(13)60683-2. PubMed PMID: 23850055.
[6] Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care.
2015;38(3):355-64. Epub 2014/09/11. doi: 10.2337/dc13-2762. PubMed PMID: 25205142.
[7] Wilding JP, Charpentier G, Hollander P, Gonzalez-Galvez G, Mathieu C, Vercruysse F, et al.
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67(12):1267-82. Epub 2013/10/15. doi: 10.1111/ijcp.12322. PubMed PMID: 24118688; PubMed Central PMCID:
PMCPMC4282288.
[8] Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36(9):2508-15. Epub 2013/04/09. doi: 10.2337/dc12-2491. PubMed PMID: 23564919; PubMed Central PMCID:
PMCPMC3747923
[9] Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16(10):1016-27. Epub 2014/06/27. doi: 10.1111/dom.12348. PubMed PMID:
24965700
[10] Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16(5):467-77. Epub 2014/02/18. doi:
10.1111/dom.12273. PubMed PMID: 24528605; PubMed Central PMCID: PMCPMC4237547.
[11] Sha S, Polidori D, Heise T, Natarajan J, Farrell K, Wang SS, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
Diabetes Obes Metab. 2014;16(11):1087-95. Epub 2014/06/19. doi: 10.1111/dom.12322. PubMed PMID: 24939043.
[12] Bode B, Stenlof K, Harris S, Sullivan D, Fung A, Usiskin K, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab. 2015;17(3):294-303. Epub 2014/12/17. doi: 10.1111/dom.12428. PubMed PMID: 25495720.
[13] Ji L, Han P, Liu Y, Yang G, Dieu Van NK, Vijapurkar U, et al. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea. Diabetes Obes Metab. 2015;17(1):23-31. Epub 2014/09/02. doi: 10.1111/dom.12385. PubMed PMID: 25175734.
[14] Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. Diabetes Care. 2015;38(12):2258-65. Epub 2015/10/22. doi: 10.2337/dc15-1730. PubMed PMID: 26486192 [15] Rodbard HW, Seufert J, Aggarwal N, Cao A, Fung A, Pfeifer M, et al. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes Obes Metab. 2016;18(8):812-9. Epub 2016/05/11. doi: 10.1111/dom.12684.
PubMed PMID: 27160639; PubMed Central PMCID: PMCPMC5089595
[16] Neal B, Perkovic V, Matthews DR. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(21):2099. Epub 2017/11/23. doi: 10.1056/NEJMc1712572.
PubMed PMID: 29166232
68
[17] Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, et al. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation.
2018;138(15):1537-50. Epub 2018/06/27. doi: 10.1161/CIRCULATIONAHA.118.035901. PubMed PMID: 29941478; PubMed Central PMCID: PMCPMC6181277
[18] Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Lancet Diabetes Endocrinol. 2018;6(9):691-704. Epub 2018/06/26. doi: 10.1016/S2213-8587(18)30141-4. PubMed PMID: 29937267
[19] Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-306.
Epub 2019/04/17. doi: 10.1056/NEJMoa1811744. PubMed PMID: 30990260.
[20] Rosenstock J, Chuck L, Gonzalez-Ortiz M, Merton K, Craig J, Capuano G, et al. Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naive Type 2 Diabetes. Diabetes Care. 2016;39(3):353-62. Epub 2016/01/21. doi: 10.2337/dc15-1736. PubMed PMID: 26786577
[21] Bays HE, Weinstein R, Law G, Canovatchel W. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring). 2014;22(4):1042-9. Epub 2013/11/15.
doi: 10.1002/oby.20663. PubMed PMID: 24227660; PubMed Central PMCID: PMCPMC4285787 [22] Lingvay I, Catarig AM, Frias JP, Kumar H, Lausvig NL, le Roux CW, et al. Efficacy and safety of
once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019. Epub 2019/09/22. doi: 10.1016/S2213-8587(19)30311-0. PubMed PMID:
31540867.
[23] List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650-7. Epub 2008/12/31. doi:
10.2337/dc08-1863. PubMed PMID: 19114612; PubMed Central PMCID: PMCPMC2660449.
[24] Wilding JP, Norwood P, T'Joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32(9):1656-62. Epub 2009/06/17. doi:
10.2337/dc09-0517. PubMed PMID: 19528367; PubMed Central PMCID: PMCPMC2732143.
[25] Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66(5):446-56. Epub 2012/03/15. doi: 10.1111/j.1742-1241.2012.02911.x. PubMed PMID: 22413962.
[26] Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35(7):1473-8. Epub 2012/03/27. doi:
10.2337/dc11-1693. PubMed PMID: 22446170; PubMed Central PMCID: PMCPMC3379599 [27] Bailey CJ, Iqbal N, T'Joen C, List JF. Dapagliflozin monotherapy in drug-naive patients with
diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012;14(10):951-9. Epub 2012/07/11. doi: 10.1111/j.1463-1326.2012.01652012;14(10):951-9.x. PubMed PMID: 22776824
[28] Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43. Epub 2013/02/22. doi: 10.1186/1741-7015-11-43.
PubMed PMID: 23425012; PubMed Central PMCID: PMCPMC3606470
[29] Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853-62.
Epub 2013/05/15. doi: 10.1111/dom.12127. PubMed PMID: 23668478; PubMed Central PMCID:
PMCPMC3906841.
[39] Nauck MA, Del Prato S, Duran-Garcia S, Rohwedder K, Langkilde AM, Sugg J, et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab.
2014;16(11):1111-20. Epub 2014/06/13. doi: 10.1111/dom.12327. PubMed PMID: 24919526.
[31] Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962-71. Epub 2013/09/27. doi:
10.1038/ki.2013.356. PubMed PMID: 24067431; PubMed Central PMCID: PMCPMC3973038.
[32] Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S, Dapagliflozin 006 Study G. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Diabetes Obes Metab. 2014;16(2):124-36. Epub 2013/08/06. doi: 10.1111/dom.12187. PubMed PMID: 23911013.
[33] Strojek K, Yoon KH, Hruba V, Sugg J, Langkilde AM, Parikh S. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther. 2014;5(1):267-83.
Epub 2014/06/13. doi: 10.1007/s13300-014-0072-0. PubMed PMID: 24920277; PubMed Central PMCID: PMCPMC4065289.
69 [34] Bolinder J, Ljunggren O, Johansson L, Wilding J, Langkilde AM, Sjostrom CD, et al. Dapagliflozin
maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab.
2014;16(2):159-69. Epub 2013/08/03. doi: 10.1111/dom.12189. PubMed PMID: 23906445.
[35] Jabbour SA, Hardy E, Sugg J, Parikh S, Study G. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37(3):740-50. Epub 2013/10/23. doi: 10.2337/dc13-0467.
PubMed PMID: 24144654
[36] Leiter LA, Cefalu WT, de Bruin TW, Xu J, Parikh S, Johnsson E, et al. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.
Diabetes Obes Metab. 2016;18(8):766-74. Epub 2016/03/25. doi: 10.1111/dom.12666. PubMed PMID: 27009868
[37] Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014;62(7):1252-62. Epub 2014/06/04. doi: 10.1111/jgs.12881. PubMed PMID:
24890683
[38] Ji L, Ma J, Li H, Mansfield TA, T'Joen C L, Iqbal N, et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther. 2014;36(1):84-100 e9. Epub 2014/01/01. doi: 10.1016/j.clinthera.2013.11.002.
PubMed PMID: 24378206.
[39] Kaku K, Kiyosue A, Inoue S, Ueda N, Tokudome T, Yang J, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab. 2014;16(11):1102-10. Epub 2014/06/10. doi: 10.1111/dom.12325.
PubMed PMID: 24909293.
[40] Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217-24. Epub 2010/06/23. doi:
10.2337/dc10-0612. PubMed PMID: 20566676; PubMed Central PMCID: PMCPMC2945163.
[41] Bailey CJ, Morales Villegas EC, Woo V, Tang W, Ptaszynska A, List JF. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabet Med. 2015;32(4):531-41. Epub 2014/11/11. doi:
10.1111/dme.12624. PubMed PMID: 25381876
[42] Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.
Diabetes Care. 2015;38(7):1218-27. Epub 2015/04/09. doi: 10.2337/dc14-0315. PubMed PMID:
25852208; PubMed Central PMCID: PMCPMC4831907.
[43] Schumm-Draeger PM, Burgess L, Koranyi L, Hruba V, Hamer-Maansson JE, de Bruin TW. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial. Diabetes Obes Metab. 2015;17(1):42-51. Epub 2014/09/10. doi:
10.1111/dom.12387. PubMed PMID: 25200570.
[44] Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S, Study G. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015;38(3):365-72. Epub 2015/01/17. doi:
10.2337/dc14-0666. PubMed PMID: 25592197
[45] Frias JP, Guja C, Hardy E, Ahmed A, Dong F, Ohman P, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(12):1004-16. Epub 2016/09/22. doi: 10.1016/S2213-8587(16)30267-4. PubMed PMID: 27651331
[46] Yang W, Han P, Min KW, Wang B, Mansfield T, T'Joen C, et al. Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial. J Diabetes. 2016;8(6):796-808. Epub 2015/11/22. doi: 10.1111/1753-0407.12357. PubMed PMID:
26589253
[47] Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4(3):211-20. Epub 2015/12/02. doi: 10.1016/S2213-8587(15)00417-9.
PubMed PMID: 26620248
[48] Mathieu C, Herrera Marmolejo M, Gonzalez Gonzalez JG, Hansen L, Chen H, Johnsson E, et al.
Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18(11):1134-7. Epub 2016/07/08. doi: 10.1111/dom.12737. PubMed PMID: 27385192.
[49] Araki E, Onishi Y, Asano M, Kim H, Ekholm E, Johnsson E, et al. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period. J Diabetes Investig. 2016;7(4):555-64. Epub 2016/05/18. doi: 10.1111/jdi.12453. PubMed PMID: 27181422; PubMed Central PMCID:
PMCPMC4931206.
70
[50] Scott R, Morgan J, Zimmer Z, Lam RLH, O'Neill EA, Kaufman KD, et al. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. Diabetes Obes Metab.
2018;20(12):2876-84. Epub 2018/07/19. doi: 10.1111/dom.13473. PubMed PMID: 30019498;
PubMed Central PMCID: PMCPMC6283039
[51] Fioretto P, Del Prato S, Buse JB, Goldenberg R, Giorgino F, Reyner D, et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes Obes Metab. 2018;20(11):2532-40. Epub 2018/06/12. doi: 10.1111/dom.13413. PubMed PMID: 29888547; PubMed Central PMCID:
PMCPMC6175614
[52] Yang W, Ma J, Li Y, Li Y, Zhou Z, Kim JH, et al. Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs:
A randomized controlled trial. J Diabetes. 2018;10(7):589-99. Epub 2017/12/08. doi: 10.1111/1753-0407.12634. PubMed PMID: 29215189.
[53] Handelsman Y, Mathieu C, Del Prato S, Johnsson E, Kurlyandskaya R, Iqbal N, et al. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2018. Epub 2018/12/01. doi: 10.1111/dom.13594. PubMed PMID: 30499237.
[54] Muller-Wieland D, Kellerer M, Cypryk K, Skripova D, Rohwedder K, Johnsson E, et al. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(11):2598-607. Epub 2018/06/28. doi:
10.1111/dom.13437. PubMed PMID: 29947099; PubMed Central PMCID: PMCPMC6220756.
[55] Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-57. Epub 2018/11/13. doi: 10.1056/NEJMoa1812389. PubMed PMID: 30415602.
[56] NCT02551874. A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin: ClinicalTrials.gov.
https://www.clinicaltrials.gov/ct2/show/results/NCT02551874; 2018 [cited 2019 March 15].
[57] Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschope D, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol.
2017;5(11):864-76. Epub 2017/09/19. doi: 10.1016/S2213-8587(17)30308-X. PubMed PMID:
28919061.
[58] Mathieu C, Dandona P, Gillard P, Senior P, Hasslacher C, Araki E, et al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018;41(9):1938-46. Epub 2018/07/22. doi: 10.2337/dc18-0623. PubMed PMID: 30026335.
[59] Kamaruddin N, Wan Seman W, Kori N, Rajoo S, MohdNoor N, Mohd Noor N, et al. Assessment ofdehydration parameters with dapagliflozin in patients with type 2 diabetes mellitus during Ramadan fasting month. Abstracts of 51st EASD Annual Meeting: Diabetologia; 2015. p. S364 [60] EUCTR2008-001921-33-DK. A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group,
Randomized, Phase 2/3 Trial to Evaluate the Glycemic Efficacy, Renal Safety, Pharmacokinetics, and Pharmacodynamics of Dapagliflozin in Subjects with Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Control. 2008. doi:
https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01858357/full.
[61] EUCTR2009-010221-39-NL. An Exploratory Phase 2 Study to Assess the Effect of Dapagliflozin on Glomerular Filtration Rate (GFR) in Subjects with Type 2 Diabetes who have Inadequate Glycemic
and Blood Pressure (BP) Control. 2009. doi:
https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01800538/full.
[62] EUCTR2010-019797-32-FI. A Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Patients with Type 2 Diabetes with not very well controlled high blood pressure taking medicine called Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB). 2011. doi:
https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01837060/full.
[63] Fadini GP, Bonora BM, Zatti G, Vitturi N, Iori E, Marescotti MC, et al. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol. 2017;16(1):42. Epub 2017/04/06. doi: 10.1186/s12933-017-0529-3. PubMed PMID: 28376855; PubMed Central PMCID:
PMCPMC5379610
[64] EUCTR2014-004599-49-BE. Double-Blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1
Diabetes Mellitus, Parallel Group. 2015. doi:
https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01831240/full.
[65] EUCTR2015-002376-24-SK. Efficacy and Safety of Dapagliflozin and Dapagliflozin plus Saxagliptinin in Combination with Metformin in Type 2 Diabetes Patients compared with Sulphonylurea. 2015. doi: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01879090/full.
71 [66] Cho KY, Nakamura A, Omori K, Takase T, Miya A, Manda N, et al. Effect of switching from
pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial. Diabetes Obes Metab. 2019;21(3):710-4. Epub 2018/10/13. doi: 10.1111/dom.13557. PubMed PMID: 30311367
[67] Rosenstock J, Perl S, Johnsson E, Garcia-Sanchez R, Jacob S. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019;21(9):2152-62. Epub 2019/05/31. doi: 10.1111/dom.13795. PubMed PMID: 31144431.
[68] McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019. Epub 2019/09/20.
doi: 10.1056/NEJMoa1911303. PubMed PMID: 31535829
[69] Pollock C, Stefansson B, Reyner D, Rossing P, Sjostrom CD, Wheeler DC, et al. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol.
2019;7(6):429-41. Epub 2019/04/18. doi: 10.1016/S2213-8587(19)30086-5. PubMed PMID:
30992195
[70] Kadowaki T, Haneda M, Inagaki N, Terauchi Y, Taniguchi A, Koiwai K, et al. Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial. Adv Ther. 2014;31(6):621-38. Epub 2014/06/25. doi:
10.1007/s12325-014-0126-8. PubMed PMID: 24958326.
[71] Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17(10):936-48.
Epub 2015/06/05. doi: 10.1111/dom.12503. PubMed PMID: 26040302; PubMed Central PMCID:
PMCPMC5034797.
[72] Roden M, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol.
2015;14:154. Epub 2015/12/25. doi: 10.1186/s12933-015-0314-0. PubMed PMID: 26701110;
PubMed Central PMCID: PMCPMC4690334.
[73] Ross S, Thamer C, Cescutti J, Meinicke T, Woerle HJ, Broedl UC. Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial. Diabetes Obes Metab.
2015;17(7):699-702. Epub 2015/04/02. doi: 10.1111/dom.12469. PubMed PMID: 25827441.
[74] Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38(3):420-8. Epub 2014/10/02. doi: 10.2337/dc14-1096. PubMed PMID: 25271206
[75] Hadjadj S, Rosenstock J, Meinicke T, Woerle HJ, Broedl UC. Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes. Diabetes Care. 2016;39(10):1718-28. Epub 2016/08/06. doi: 10.2337/dc16-0522. PubMed PMID: 27493136.
[76] Softeland E, Meier JJ, Vangen B, Toorawa R, Maldonado-Lutomirsky M, Broedl UC. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial. Diabetes Care.
2017;40(2):201-9. Epub 2016/12/04. doi: 10.2337/dc16-1347. PubMed PMID: 27913576
[77] Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, et al. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. Diabetes Care.
2018;41(12):2560-9. Epub 2018/10/06. doi: 10.2337/dc18-1749. PubMed PMID: 30287422.
[79] Ridderstrale M, Rosenstock J, Andersen KR, Woerle HJ, Salsali A, investigators E-RHHSt.
Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial. Diabetes Obes Metab. 2018;20(12):2768-77.
Epub 2018/07/03. doi: 10.1111/dom.13457. PubMed PMID: 29961998
[80] Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37(7):1815-23. Epub 2014/06/16. doi: 10.2337/dc13-3055. PubMed PMID: 24929430 [81] Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, et al. Efficacy and safety of
empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic
empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic